Clinical trial
A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis
NCT03117569 is registered in ClinicalTrials.gov with Kirby Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis
- Lead sponsor
- Kirby Institute
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- August 21, 2017
- Completion date
- December 19, 2018
- Enrollment
- 380 (actual)
- Sites
- 33
Conditions
As the registry lists them; a condition with its own page is linked.